Novavax says its new Indian vaccine plant will be operational in four months with sufficient capacity to help meet local demand for seasonal influenza vaccines.
Novavax has entered into a deal with Xcellerex to boost production of its H1N1 vaccine, which is entering clinical trials in Mexico, using the CMO’s FlexFactory disposable biomanufacturing platform.
Novavax’ VLP delivery system has been the subject of industry excitement this week after the US firm released Ph II data showing that a combination seasonal influenza vaccine based on the technology is effective and well tolerated.
The Spanish Ministry of Health is leading a €60m ($84.9m) programme that will build the country’s first vaccine production facility and use Novavax’s recombinant virus-like-particle (VLP) technology.
Crucell has granted a license for its PER.C6 cell line technology
to Novavax, allowing the latter company to start offering contract
manufacturing services for vaccines.